Seems like we disagree on just about everything. It is pretty astonishing to me that you dismiss the investment potential of ADCs as well as anti-cancer drugs. A barrier to entry is quite different from efficacy, safety and timing. ADC that are already shown to be effective as single agents will become the backbone of broader indications as combination drugs, especially with immuno-modulators. There are a lot of entrants into the T cell modulation field because the market is so broad, and successful therapies have longer duration of treatment.
You have told us a lot of what you don't like but not what you do like, going as far as to complain about what is discussed on this aboard. How about enlightening us on the what you do like?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.